L. Pei

发表

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study*

F. Cavalli, H. van de Velde, Jie Jin, 2019, Leukemia & lymphoma.

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

F. Cavalli, J. Novak, J. Zaucha, 2018, Leukemia & lymphoma.

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

F. Cavalli, H. van de Velde, J. Drach, 2017, Haematologica.

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

L. Shih, H. van de Velde, Jie Jin, 2018, OncoTargets and therapy.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P. Sonneveld, M. Béné, M. Vekemans, 2019, The Lancet.

Dexamethasone plus lenalidomide in treatment of multiple myeloma

Ya Mingxi, Z. Hao, L. Pei, 2011 .

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

P. Sonneveld, M. Béné, P. Moreau, 2022, Haematologica.

Teclistamab in Relapsed or Refractory Multiple Myeloma.

A. Krishnan, J. Goldberg, H. Nahi, 2022, The New England journal of medicine.

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

A. Krishnan, J. Goldberg, J. Infante, 2021, The Lancet.

Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

P. Sonneveld, M. Béné, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.

P. Sonneveld, M. Béné, P. Moreau, 2019, Journal of Clinical Oncology.

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

D. Esseltine, J. Miguel, A. Oriol, 2016, Annals of Hematology.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

D. Esseltine, D. Reece, V. Kukreti, 2014, Blood.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

F. Cavalli, Jie Jin, J. Drach, 2015, The New England journal of medicine.

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

A. Krishnan, J. Goldberg, H. Nahi, 2020 .

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

P. Sonneveld, P. Moreau, X. Leleu, 2019, Blood.

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

P. Sonneveld, P. Moreau, T. Facon, 2021, Haematologica.

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

H. Einsele, P. Moreau, X. Leleu, 2023, Advances in therapy.

Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

P. Sonneveld, M. Béné, P. Moreau, 2019, Journal of Clinical Oncology.

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.

H. Goldschmidt, P. Moreau, T. Parekh, 2023, Clinical lymphoma, myeloma & leukemia.

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

A. Krishnan, A. Nooka, T. Parekh, 2023, Journal of comparative effectiveness research.

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma

A. Nooka, R. Verona, M. Qi, 2023, Cancer.

Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, T. Facon, 2019, HemaSphere.

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

J. Goldberg, P. Moreau, R. Verona, 2022, Blood.

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

H. Einsele, P. Sonneveld, M. Boccadoro, 2022, Blood.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).

F. Cavalli, T. Robak, H. Velde, 2014 .

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

R. Verona, M. Samtani, C. Uhlar, 2023, Targeted Oncology.

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

F. Ghilotti, A. Perrot, S. Manier, 2023, Advances in therapy.

Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

J. Diels, S. Van Sanden, L. Pei, 2024, Current medical research and opinion.